Just one week until the DFW Hospital Council (DFWHC) and Alexion Pharmaceuticals, Inc. webinar “Andexanet alfa Budget Impact Model” on Wednesday, May 26 from 1:00-2:00 p.m., CDT.
Join us for this complimentary virtual discussion on health economics. Using an approved model structure developed with clinical guidance, the speakers will detail the cost-effectiveness and budgetary impact of andexanet alfa on selected health outcomes and costs.
Speakers will include Kelly McNeil-Posey, director of health economics and outcomes research at Alexion; Sharon Williams, director of U.S. strategic accounts at Alexion; and Stephen Love, president/CEO of DFWHC.
You can register here.
For information, please contact Chris Wilson at email@example.com.